Damon R. Reed, MD, compared the carefully considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.
Damon R. Reed, MD
Advertisement
Damon R. Reed, MD, is head of the Solid Tumor Oncology Division in Pediatrics at Memorial Sloan Kettering Cancer Center.
Articles by Damon R. Reed, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5